This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What To Expect From The Crazy Earnings Season Ahead
by Daniel Laboe
Are Netflix's disappointing results a foreshadowing of what is to come from the most parabolic tech stocks this earnings season?
Ceylad Gets FDA Nod to Begin Phase I Study on CAR T Candidate
by Zacks Equity Research
Celyad (CYAD) gets the FDA's permission to begin a phase I study on its lead CAR T candidate, CYAD-211, for the treatment of relapsed/refractory multiple myeloma.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Biogen/Eisai's New BAN2401 Study for Alzheimer's Begins
by Zacks Equity Research
A new phase III study has been initiated to evaluate Biogen (BIIB) and Eisai's BAN2401 to treat preclinical Alzheimer's disease.
Biogen Files BLA for Alzheimer's Drug Aducanumab, Stock Up
by Zacks Equity Research
If Biogen's (BIIB) aducanumab is approved by the FDA, it will become the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.
Endo (ENDP) Obtains FDA Approval for Cellulite Treatment
by Zacks Equity Research
Endo (ENDP) gains FDA approval for Qwo (collagenase clostridium histolyticum-aaes) for the treatment of cellulite.
Novartis Gets EC Approval for Enerzair Breezhaler for Asthma
by Zacks Equity Research
Novartis (NVS) gets EC approval for Enerzair Breezhaler as a maintenance treatment for asthma.
The Zacks Analyst Blog Highlights: Novartis, Equinix, Newmont, Enterprise Products Partners and Franco-Nevada
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, Equinix, Newmont, Enterprise Products Partners and Franco-Nevada
Top Analyst Reports for Novartis, Equinix & Newmont
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), Equinix (EQIX) and Newmont (NEM).
Amgen Gets Favorable Appeals Court Ruling for Enbrel Patent
by Zacks Equity Research
An appeals court ruled in Amgen's (AMGN) favor in a case challenging the validity of two patents on its top-selling medicine, Enbrel.
Novartis Gets Positive CHMP View for Cosentyx Label Expansion
by Zacks Equity Research
Novartis' (NVS) Cosentyx gets positive CHMP opinion for moderate-to-severe plaque psoriasis in children and adolescents aged 6-18 years.
Bristol Myers & Acceleron Obtain EC Approval for Reblozyl
by Zacks Equity Research
Bristol Myers (BMY) and partner Acceleron win EC approval of Reblozyl (luspatercept) for two indications.
AbbVie's Eye Disorder Candidate Gets Complete Response Letter
by Zacks Equity Research
AbbVie (ABBV) unit Allergan's abicipar pegol demonstrates unfavorable benefit-risk ratio in patients with nAMD, an eye disorder. The FDA issues a complete response letter.
Global Blood to Seek Approval of Oxbryta in Europe for SCD
by Zacks Equity Research
Global Blood (GBT) plans to seek approval for Oxbryta tablets to treat hemolytic anemia in SCD patients aged 12 years and older in Europe.
Novartis Discontinues HCQ Study Due to Enrollment Challenges
by Zacks Equity Research
Novartis (NVS) abandons its HCQ study in COVID-19 patients due to enrollment challenges.
Alpine Skyrockets on License Deal With AbbVie for ALPN-101
by Zacks Equity Research
Alpine (ALPN) signs an agreement with AbbVie granting exclusive worldwide option and license to its pipeline candidate, ALPN-101. The deal significantly boosts Alpine's funds.
Pharma Stock Roundup: FDA Approvals to MRK, LLY, NVS and GSK's Drugs
by Kinjel Shah
FDA approves expanded labels of Merck (MRK), Novartis (NVS) and Glaxo (GSK) drugs and Lilly's (LLY) new insulin.
Novartis' (NVS) Cosentyx Gets FDA Nod for New Indication
by Zacks Equity Research
Novartis' (NVS) Cosentyx wins FDA approval for a fourth indication ??? active non-radiographic axial spondyloarthritis (nr-axSpA).
Lilly Gains as Verzenio Meets Early Breast Cancer Study Goal
by Zacks Equity Research
Lilly's (LLY) phase III study on Verzenio in HR+, HER2- early breast cancer met its primary endpoint of invasive disease-free survival.
Bayer Initiates a Phase III Study in Heart Failure Patients
by Zacks Equity Research
Bayer (BAYRY) initiates a phase III study to evaluate finerenone compared to placebo in more than 5,500 symptomatic heart failure patients with a left ventricular ejection fraction.
FDA Ends Hydroxychloroquine's Emergency Use for Coronavirus
by Kinjel Shah
The FDA said that chloroquine and hydroxychloroquine are unlikely to prove effective in treating COVID-19 as the known benefits outweigh the risks.
Novartis' (NVS) Beovu Gets FDA Approval for Label Update
by Zacks Equity Research
Novartis' (NVS) ophthalmology drug, Beovu, gets update for safety information regarding retinal vasculitis and retinal vascular occlusion.
The Zacks Analyst Blog Highlights: Mastercard, Novartis, Boeing Company, Sanofi and Honeywell International
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, Novartis, Boeing Company, Sanofi and Honeywell International
Global Blood Seeks Label Expansion of Oxbryta in Kids With SCD
by Zacks Equity Research
Global Blood (GBT) seeks label expansion of Oxbryta for the treatment of SCD in children aged 4 to 11 years.
Bayer (BAYRY) Submits Applications for Heart Failure Drug
by Zacks Equity Research
Bayer (BAYRY) seeks approval of chronic heart failure drug, vericiguat, in the EU and Japan.